Cabergoline in Metastatic Breast Cancer

['lizbeth]

Cabergoline in Metastatic Breast Cancer

This study is currently recruiting participants.
Verified September 2013 by Northwestern University
Sponsor:
Northwestern University
Collaborator:
Lynn Sage Foundation
Information provided by (Responsible Party):
Northwestern University

ClinicalTrials.gov Identifier:
NCT01730729
First received: November 15, 2012
Last updated: September 17, 2013
Last verified: September 2013
History of Changes

• Full Text View
• Tabular View
• No Study Results Posted
• Disclaimer
• How to Read a Study Record

Purpose Prolactin is a hormone produced in the pituitary gland. Previous studies have revealed that elevated levels of the hormone prolactin might be associated with an increased risk of breast cancer. Cabergoline has been shown to lower prolactin levels in the blood.
The purpose of this study is to evaluate the effectiveness of cabergoline in treating metastatic breast cancer disease in those who test positive for the prolactin receptor.